Skip to content

Establishing the cascade of care for hepatitis C in England—benchmarking to monitor impact of direct acting antivirals

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)482-490
Number of pages9
JournalJournal of Viral Hepatitis
Volume25
Issue number5
Early online date15 Dec 2017
DOIs
DateAccepted/In press - 31 Oct 2017
DateE-pub ahead of print - 15 Dec 2017
DatePublished (current) - 1 May 2018

Abstract

Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case finding, referral, treatment uptake and retention in care. Using data from the sentinel surveillance of blood-borne virus (SSBBV) testing between 2005 and 2014, we investigate the continuum of care of those tested for HCV in England. Persons ≥1 year old with an anti-HCV test and subsequent RNA tests between 2005 and 2014 reported to SSBBV were collated. We describe the cascade of care, as the patient pathway from a diagnostic test, referral into care, treatment and patient outcomes. Between 2005 and 2014, 2 390 507 samples were tested for anti-HCV, corresponding to 1 766 515 persons. A total of 53 038 persons (35 190 men and 17 165 women) with anti-HCV positive were newly reported to SSBBV. An RNA test was conducted on 77.0% persons who were anti-HCV positive, 72.3% of whom were viraemic (RNA positive) during this time period, 21.4% had evidence of treatment and 3130 49.5% had evidence of a sustained virological response (SVR). In multivariable models, confirmation of viraemia by RNA test varied by age and region/test setting; evidence of treatment varied by age, year of test and region/test setting; and SVR varied by age, year of test and region/setting of test. In conclusion, our findings provide HCV cascade of care estimates prior to the introduction of direct acting antivirals. These findings provide important baseline cascade estimates to benchmark progress towards elimination of HCV as a major public health threat.

    Research areas

  • barriers, cascade, DAA HCV, SVR, treatment

Download statistics

No data available

Documents

Documents

  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at https://onlinelibrary.wiley.com/doi/full/10.1111/jvh.12844 . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 633 KB, PDF document

DOI

View research connections

Related faculties, schools or groups